I was under the impression that we had had some dialogue on this already.  Our expectation is that we will get time to assess any novel aspects of RCC that could be important in the commercialization of the vaccine and Inhibitors. If we are convinced that the release of the genome will not undermine the commercialization then we will be supportive of its release. Therefore it would be good to be able to discuss these Methanomassillicoccales genomes and how inhibition of the other methanogen's might affect there activity in the rumen. We do want to find some sensible middle ground if we can but won't approve until we are sure of that. 